Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19282553 | PLANT COLONIZATION ASSAYS USING NATURAL MICROBIAL BARCODES | July 2025 | March 2026 | Allow | 8 | 1 | 0 | No | No |
| 19204075 | NUCLEIC ACID MOLECULES AND USES THEREOF | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19077147 | ANTIBIOTIC FREE TREATMENT OF MASTITIS | March 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19012978 | VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOF | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18940501 | ARTIFICIAL RNA MOLECULES ENCODING A NOROVIRUS ANTIGEN AND USES THEREOF | November 2024 | September 2025 | Allow | 10 | 1 | 0 | No | No |
| 18792611 | COXSACKIEVIRUS B4 STRAIN AND APPLICATION THEREOF | August 2024 | May 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18667247 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | May 2024 | July 2025 | Allow | 14 | 1 | 0 | No | No |
| 18665309 | RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/PIV3 F PROTEIN AND USES THEREOF | May 2024 | January 2026 | Allow | 20 | 1 | 0 | No | No |
| 18660609 | PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM | May 2024 | February 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18655777 | METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3 | May 2024 | October 2025 | Allow | 18 | 2 | 0 | No | No |
| 18644438 | ANTIBIOTIC FREE TREATMENT OF MASTITIS | April 2024 | December 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18622330 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | March 2024 | June 2025 | Allow | 14 | 1 | 0 | No | No |
| 18615838 | METHOD OF PRODUCING AN IMMUNOGENIC COMPOSITION | March 2024 | September 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18614158 | PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODS | March 2024 | March 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18443262 | METHOD FOR THE DETECTION AND QUANTIFICATION OF ADENO-ASSOCIATED VIRUSES (AAVs) USING AN AFFINITY MATRIX | February 2024 | January 2025 | Allow | 11 | 2 | 0 | No | No |
| 18430151 | METHODS OF IMMUNOTHERAPY | February 2024 | December 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18418127 | RSV RNA VACCINES | January 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18580550 | PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME | January 2024 | December 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18396787 | Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof | December 2023 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18394486 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE | December 2023 | December 2024 | Allow | 12 | 0 | 0 | No | No |
| 18542330 | RECOMBINANT HERPESVIRUS OF TURKEY VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF | December 2023 | June 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18530421 | FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS | December 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18516237 | PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF | November 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18511123 | FOOT-AND-MOUTH DISEASE VACCINE | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18498879 | METHOD FOR LARGE-SCALE PRODUCTION OF LENTIVIRUS BY USING GMP-LEVEL SERUM-FREE SUSPENSION CELLS | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18492535 | ONCOLYTIC VIRUS IMPROVED IN SAFETY AND ANTICANCER EFFECT | October 2023 | October 2024 | Allow | 12 | 1 | 1 | No | No |
| 18287248 | LIQUID SIX COMBINED VACCINE COMPOSITION | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18376177 | Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18285124 | INFLUENZA VACCINE FOR INTRANASAL ADMINISTRATION | September 2023 | January 2026 | Abandon | 28 | 0 | 0 | No | No |
| 18476042 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18242627 | HORN FLY VACCINE COMPOSITIONS AND METHODS OF MAKING SAME | September 2023 | February 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18461369 | PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | September 2023 | February 2025 | Allow | 17 | 2 | 0 | No | No |
| 18366839 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE | August 2023 | March 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18354172 | ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES | July 2023 | July 2024 | Allow | 12 | 1 | 1 | No | No |
| 18216531 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | June 2023 | October 2024 | Allow | 15 | 1 | 1 | No | No |
| 18334573 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | June 2023 | October 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18331083 | VIRUS-LIKE PARTICLES AND METHODS OF USE | June 2023 | July 2024 | Allow | 14 | 2 | 0 | No | No |
| 18250761 | Canine Parvovirus | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18018316 | GOLD NANOPARTICLE INTRANASAL VACCINE COMPOSITIONS | January 2023 | March 2026 | Allow | 37 | 2 | 0 | No | No |
| 18146995 | BUNYAVIRALES VACCINE | December 2022 | April 2025 | Allow | 28 | 1 | 2 | No | No |
| 18085478 | VACCINES FOR IN VIVO EXPRESSION OF NUCLEIC ACIDS AND METHODS OF USING THE SAME | December 2022 | June 2025 | Allow | 30 | 1 | 0 | No | No |
| 18009895 | PANDEMIC-PREPAREDNESS COCKTAIL TO FIGHT CORONAVIRUS OUTBREAKS | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18000900 | SEROLOGICAL ASSAYS FOR SARS-COV-2 | December 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18000558 | ATTENUATED VARIANT OF THE RIFT VALLEY FEVER VIRUS, COMPOSITION COMPRISING SAME, AND USES THEREOF | December 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 18055193 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | November 2022 | July 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17997749 | N PROTEIN EPITOPE MUTATION MARKER FOR PREPARING EPITOPE DELETION-MARKED VACCINE STRAIN OF TYPE II PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND USE THEREOF | November 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17997527 | POLYNUCLEOTIDES ENCODING SARS-COV-2 ANTIGENS AND USE THEREOF IN THE MEDICAL FIELD AS VACCINES | October 2022 | March 2026 | Allow | 41 | 1 | 1 | No | No |
| 17913822 | Methods for Providing a Vaccine | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17948752 | Cocktail Vaccine of Recombinant African Swine Fever Virus (ASFV) Antigen and Use Thereof | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17889737 | DEVELOPMENT OF MOSAIC VACCINES AGAINST FOOT AND MOUTH DISEASE VIRUS SEROTYPE O | August 2022 | August 2025 | Allow | 36 | 1 | 0 | No | No |
| 17886357 | METHOD FOR DETERMINING THE LOADING STATE OF AN AAV PARTICLE BY NUCLEAR MAGNETIC RESONANCE RELAXOMETRY | August 2022 | December 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17799118 | INTRANASAL mRNA VACCINES | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17813178 | VECTORS FOR ELICITING IMMUNE RESPONSES TO NON-DOMINANT EPITOPES IN THE HEMAGGLUTININ (HA) PROTEIN | July 2022 | July 2024 | Allow | 24 | 1 | 0 | No | No |
| 17791678 | RECOMBINANT VIRUSES EXPRESSING ALPHA-1, 3-GALACTOSYLTRANSFERASE AND USES THEREOF | July 2022 | January 2026 | Allow | 43 | 1 | 0 | No | No |
| 17791076 | COMBINED NOROVIRUS AND ROTAVIRUS VACCINE COMPOSITION AND METHODS OF PREPARATION | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17758182 | AFRICAN SWINE FEVER VIRUS CHIMERIC PROTEIN, VACCINE COMPOSITION, PREPARATION METHOD AND USE THEREOF | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17784081 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | June 2022 | January 2026 | Allow | 43 | 2 | 0 | No | No |
| 17783478 | INACTIVATED PISCINE ORTHOREOVIRUS VACCINE | June 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17779811 | ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140 | May 2022 | December 2025 | Allow | 43 | 1 | 1 | No | No |
| 17776896 | HIV Immunogens, Vaccines, and Methods Related Thereto | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17774315 | ENGINEERED VIRAL CAPSID POLYPEPTIDES AND USES THEREOF | May 2022 | December 2025 | Allow | 44 | 2 | 1 | No | No |
| 17755663 | F-GENOTYPE MUMPS VIRUS ATTENUATED STRAIN AND CONSTRUCTION METHOD THEREFOR AND APPLICATION THEREOF | May 2022 | July 2025 | Allow | 39 | 1 | 0 | No | No |
| 17735010 | METHODS FOR LOWERING THE INFECTION RATE OF VIRUSES | May 2022 | April 2025 | Abandon | 35 | 5 | 1 | Yes | No |
| 17771736 | IMPROVED VACCINES FOR RECURRENT RESPIRATORY PAPILLOMATOSIS AND METHODS FOR USING THE SAME | April 2022 | December 2025 | Allow | 44 | 2 | 0 | No | No |
| 17768074 | COMBINED VACCINE AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS AND METHOD THEREOF FOR INDUCING IMMUNE RESPONSE | April 2022 | July 2025 | Allow | 40 | 1 | 0 | No | No |
| 17766989 | Chimeric Antigen Receptors against Human Cytomegalovirus | April 2022 | January 2026 | Allow | 45 | 1 | 1 | No | No |
| 17765760 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | March 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17707613 | METHODS OF PRODUCING AND CHARACTERIZING VIRUS VACCINE AND VIRUS VACCINE COMPOSITION | March 2022 | January 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17763184 | BIODEGRADABLE NANOCOMPLEX VACCINES, METHODS FOR SUPPRESSION OF HEPAPITIS B VIRUS REPLICATION AND HEPAPITIS B VIRUS SURFACE ANTIGEN SECRETION | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17688366 | Bovine Herpesvirus Detection and Treatment | March 2022 | October 2025 | Abandon | 44 | 3 | 0 | No | No |
| 17634488 | PORCINE CIRCOVIRUS TYPE 2 VLP VACCINE | February 2022 | October 2025 | Allow | 45 | 2 | 0 | No | No |
| 17634272 | IMMUNOGENIC COMPOSITION | February 2022 | October 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17579447 | Chimeric Papilloma Virus L1 Protein | January 2022 | June 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17628403 | A PORCINE CIRCOVIRUS TYPE 2 (PCV2) VACCINE | January 2022 | September 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17552288 | SYSTEM FOR RAPID ON-SITE TESTING FOR AIRBORNE AND OTHER PATHOGENS | December 2021 | November 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17618625 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE VIRUS | December 2021 | September 2024 | Allow | 33 | 0 | 0 | No | No |
| 17544518 | VIRAL NANOPARTICLE MULTIMERS | December 2021 | March 2025 | Allow | 39 | 2 | 0 | No | No |
| 17609822 | A VACCINE COMPRISING A NANOPARTICLE ENCAPSULATING EPITOPES AND ADJUVANT FOR NEUTRALIZING VIRUS INFECTION | November 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17485857 | Paramyxovirus and uses thereof | September 2021 | March 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17469313 | COMPOSITIONS COMPRISING A NOROVIRUS NUCLEIC ACID AND METHODS OF USE THEREOF | September 2021 | August 2024 | Allow | 35 | 2 | 0 | No | No |
| 17468419 | IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES | September 2021 | April 2025 | Allow | 43 | 1 | 1 | No | No |
| 17436791 | NOVEL CORONAVIRUS ANTIBODY DETECTION KIT BASED ON MAGNETIC PARTICLE CHEMILUMINESCENCE | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17431987 | ROTAVIRUS VP7 FUSION PROTEINS AND ROTAVIRUS-LIKE PARTICLES COMPRISING THEM | August 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17395242 | METHOD FOR THE RAPID DIAGNOSIS OF COVID-19 USING A MOBILE GENETIC TESTING LABORATORY | August 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17428967 | IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES | August 2021 | October 2024 | Allow | 39 | 2 | 0 | No | No |
| 17421278 | PLANT COLONIZATION ASSAYS USING NATURAL MICROBIAL BARCODES | July 2021 | June 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17420442 | COMPOSITIONS AND METHODS FOR DETECTING HUMAN PAPILLOMAVIRUS | July 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17418131 | PHARMACEUTICAL PREPARATION FOR TREATING HEPATITIS B, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2021 | January 2025 | Allow | 43 | 1 | 0 | No | No |
| 17351363 | IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | June 2021 | October 2024 | Allow | 40 | 1 | 0 | No | No |
| 17416199 | VACCINES AGAINST POWASSAN VIRUS, AND METHODS OF USING SAME | June 2021 | November 2025 | Allow | 53 | 3 | 0 | No | No |
| 17415305 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | June 2021 | July 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17414187 | Prime-Boost Vaccination Regimen | June 2021 | July 2024 | Allow | 37 | 1 | 0 | No | No |
| 16978919 | ANTI-PD-1 VACCINE COMPOSITION | June 2021 | December 2024 | Abandon | 52 | 0 | 1 | No | No |
| 17312235 | VACCINE FOR PREVENTING OR TREATING CONGENITAL INFECTION WITH CYTOMEGALOVIRUS | June 2021 | February 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17341928 | CORONAVIRUS VACCINE AND METHODS OF USE THEREOF | June 2021 | May 2025 | Allow | 47 | 2 | 1 | No | No |
| 17299852 | HIV VACCINE IMMUNOGENS | June 2021 | October 2024 | Allow | 41 | 1 | 1 | No | No |
| 17289850 | TOOLS FOR DETECTING COCOA SWOLLEN SHOOT VIRUS COAT PROTEIN ANTIGEN | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17288208 | VSG-BASED VACCINATION AND ANTIBODY GENERATION PLATFORM FOR THE TREATMENT OF DISEASES | April 2021 | December 2024 | Allow | 43 | 1 | 1 | No | No |
| 17236099 | THERAPEUTIC MITIGATION OF EPITHELIAL INFECTION | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | No |
| 17285045 | VIRUS VACCINE | April 2021 | May 2025 | Abandon | 49 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FOLEY, SHANON A.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 76.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner FOLEY, SHANON A works in Art Unit 1671 and has examined 163 patent applications in our dataset. With an allowance rate of 92.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner FOLEY, SHANON A's allowance rate of 92.0% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by FOLEY, SHANON A receive 1.83 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by FOLEY, SHANON A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +5.4% benefit to allowance rate for applications examined by FOLEY, SHANON A. This interview benefit is in the 31% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.3% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 66.0% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 81.2% of appeals filed. This is in the 74% percentile among all examiners. Of these withdrawals, 61.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 42.9% are granted (fully or in part). This grant rate is in the 34% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.3% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.